NEW BRUNSWICK, N.J., May 14 /PRNewswire-USNewswire/ — As many
as 5.3 million Americans, and 35 million people worldwide, are
living with Alzheimer’s disease (AD), a devastating
neurodegenerative illness characterized by memory loss, cognitive
decline and widespread destruction of neurons in the brain.
Today, there is no definitive diagnosis for the disease, and
no treatment to cure it.
AD is the most common form of dementia and, with our aging
population, the number of people who will develop the disease is
expected to increase dramatically in the future.
With Foundation Venture Capital Group, LLC’s, latest investment,
James M. Golubieski, president, is
hoping to help to lower those numbers dramatically. That’s
why the company has made an initial investment of $175,000, which can go up to $500,000 pending completion of certain
milestones, to Durin Technologies, Inc., a start-up company
developing a test that requires only a drop of blood to diagnose
the disease.
“My research centers on the fact that autoantibodies are
involved in the degenerative mechanism of AD,” explained Robert Nagele, PhD, founder of Durin
Technologies and a researcher at the Institute for Successful Aging
at the UMDNJ-School of Osteopathic Medicine in Stratford, NJ.
Dr. Nagele noted that the concept is gaining support in the
scientific community and a number of pharmaceutical companies are
seriously looking into it to help diagnose, and later treat,
AD.
“We are hopeful that Dr. Nagele’s research will help to fill an
unmet need in the diagnostic and pharmaceutical industries
‘/>”/>
